Current Report Filing (8-k)
December 29 2021 - 4:01PM
Edgar (US Regulatory)
0001106644
false
CN
0001106644
2021-12-26
2021-12-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): December
26, 2021
CHINA PHARMA HOLDINGS, INC.
(Exact name of Registrant as specified in charter)
Nevada
|
|
001-34471
|
|
73-1564807
|
(State or other jurisdiction
|
|
(Commission File No.)
|
|
(IRS Employer
|
of Incorporation)
|
|
|
|
Identification No.)
|
Second Floor, No. 17, Jinpan Road
Haikou, Hainan Province, China 570216
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
+86 898-6681-1730 (China)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
|
Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
|
☐
|
|
Soliciting material pursuant to Rule14a-12 under the Exchange Act (17CFR240.14a-12)
|
☐
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
|
☐
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock
|
|
CPHI
|
|
NYSE American
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
On December 26, 2021, the Company held its annual
shareholders meeting for the fiscal year ended December 31, 2020 (the “Annual Meeting”). Holders of 35,348,061 shares of the
Company’s common stock were present in person or by proxy at the Annual Meeting, representing 55% of the total outstanding shares
of common stock and therefore constituting a quorum of more than one-third of the shares outstanding and entitled to vote at the Annual
Meeting as of the record date.
The final voting results for the matters submitted
to a vote of shareholders at the meeting are as follows. No broker non-votes were counted for the proposals.
|
1.
A proposal to elect five director nominees to our Board of Directors:
|
Director’s Name
|
|
Votes For
|
|
|
Votes Withheld
|
|
Zhilin Li
|
|
|
25,934,289
|
|
|
|
86,371
|
|
Heung Mei Tsui
|
|
|
25,933,285
|
|
|
|
87,375
|
|
Gene Michael Bennett
|
|
|
25,495,265
|
|
|
|
525,394
|
|
Yingwen Zhang
|
|
|
25,436,803
|
|
|
|
583,857
|
|
Baowen Dong
|
|
|
25,484,804
|
|
|
|
535,856
|
|
Pursuant to the foregoing votes, Zhilin Li and Heung
Mei Tsui were elected to serve as our non-independent directors until the date of the annual shareholders meeting in three years and until
their successors are elected and qualified. Gene Michael Bennett, Yingwen Zhang and Baowen Dong were elected to serve as our independent
directors until the next annual meeting and until their successors are elected and qualified.
|
2.
|
A proposal to adopt the Amendment No.2 to the Company’s 2010 Long-Term Incentive Plan:
|
Votes For
|
|
|
Votes Against
|
|
|
Abstentions
|
|
|
25,917,951
|
|
|
|
94,918
|
|
|
|
7,791
|
|
Pursuant to the foregoing votes, the Amendment No. 2 to the Company’s
2010 Long-Term Incentive Plan was approved and adopted.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
December 28, 2021
|
CHINA PHARMA HOLDINGS, INC.
|
|
|
|
By:
|
/s/ Zhilin Li
|
|
Name:
Title:
|
Zhilin Li
President
and Chief Executive Officer
|
China Pharma (AMEX:CPHI)
Historical Stock Chart
From Mar 2024 to Apr 2024
China Pharma (AMEX:CPHI)
Historical Stock Chart
From Apr 2023 to Apr 2024